COLL vs. SVA, STML, INZY, NKTR, SPPI, NUVL, ALKS, PRGO, CRNX, and AXSM
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Sinovac Biotech (SVA), Stemline Therapeutics (STML), Inozyme Pharma (INZY), Nektar Therapeutics (NKTR), Spectrum Pharmaceuticals (SPPI), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), and Axsome Therapeutics (AXSM). These companies are all part of the "medical" sector.
Sinovac Biotech (NASDAQ:SVA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
Collegium Pharmaceutical has a consensus target price of $39.00, suggesting a potential upside of 17.68%. Given Sinovac Biotech's higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Sinovac Biotech.
Collegium Pharmaceutical has higher revenue and earnings than Sinovac Biotech.
Collegium Pharmaceutical received 119 more outperform votes than Sinovac Biotech when rated by MarketBeat users. However, 67.99% of users gave Sinovac Biotech an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.
Collegium Pharmaceutical has a net margin of 16.46% compared to Collegium Pharmaceutical's net margin of 0.00%. Sinovac Biotech's return on equity of 104.98% beat Collegium Pharmaceutical's return on equity.
In the previous week, Collegium Pharmaceutical had 12 more articles in the media than Sinovac Biotech. MarketBeat recorded 13 mentions for Collegium Pharmaceutical and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.56 beat Collegium Pharmaceutical's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.
Summary
Collegium Pharmaceutical beats Sinovac Biotech on 11 of the 12 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
